|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/15/22 Cell Source, Inc. 10-K 12/31/21 75:11M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.93M
2: EX-4.1 Instrument Defining the Rights of Security Holders HTML 22K
3: EX-10.36A Material Contract HTML 50K
4: EX-10.39B Material Contract HTML 50K
5: EX-10.63A Material Contract HTML 30K
6: EX-10.68 Material Contract HTML 53K
7: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
14: R1 Cover HTML 87K
15: R2 Consolidated Balance Sheets HTML 117K
16: R3 Consolidated Balance Sheets (Parenthetical) HTML 51K
17: R4 Consolidated Statements of Operations HTML 78K
18: R5 Consolidated Statements of Changes in HTML 167K
Stockholders' Deficiency
19: R6 Consolidated Statements of Cash Flows HTML 165K
20: R7 Business Organization, Nature of Operations and HTML 28K
Risks and Uncertainties
21: R8 Going Concern and Management?s Plans HTML 30K
22: R9 Summary of Significant Accounting Policies HTML 94K
23: R10 Fair Value HTML 134K
24: R11 Accrued Expenses HTML 40K
25: R12 Accrued Compensation HTML 42K
26: R13 Advances Payable HTML 27K
27: R14 Notes Payable HTML 222K
28: R15 Income Taxes HTML 61K
29: R16 Stockholders? Deficiency HTML 241K
30: R17 Commitments and Contingencies HTML 46K
31: R18 Related Party Transactions HTML 28K
32: R19 Subsequent Events HTML 38K
33: R20 Summary of Significant Accounting Policies HTML 128K
(Policies)
34: R21 Summary of Significant Accounting Policies HTML 42K
(Tables)
35: R22 Fair Value (Tables) HTML 131K
36: R23 Accrued Expenses (Tables) HTML 38K
37: R24 Accrued Compensation (Tables) HTML 41K
38: R25 Notes Payable (Tables) HTML 110K
39: R26 Income Taxes (Tables) HTML 57K
40: R27 Stockholders? Deficiency (Tables) HTML 160K
41: R28 Going Concern and Management?s Plans (Details HTML 48K
Narrative)
42: R29 Schedule of Weighted Average Dilutive Common HTML 35K
Shares Anti-dilutive (Details)
43: R30 Schedule of Weighted Average Dilutive Common HTML 22K
Shares Anti-dilutive (Details) (Parenthetical)
44: R31 Summary of Significant Accounting Policies HTML 45K
(Details Narrative)
45: R32 Schedule of Changes in Fair Value of Liabilities HTML 68K
Measured at Fair Value on a Recurring Basis
(Details)
46: R33 Schedule of Assumptions Used for Valuation of HTML 40K
Level 3 Liabilities (Details)
47: R34 Fair Value (Details Narrative) HTML 24K
48: R35 Schedule of Accrued Expenses (Details) HTML 36K
49: R36 Schedule of Accrued Compensation (Details) HTML 42K
50: R37 Advances Payable (Details Narrative) HTML 33K
51: R38 Schedule of Notes Payable (Details) HTML 36K
52: R39 Schedule of Notes Payable Due to Related Parties HTML 28K
(Details)
53: R40 Schedule of Convertible Notes Payable (Details) HTML 39K
54: R41 Schedule of Convertible Notes Payable (Details) HTML 34K
(Parenthetical)
55: R42 Schedule of Convertible Notes Payable Due to HTML 27K
Related Parties (Details)
56: R43 Schedule of Convertible Notes Payable Due to HTML 24K
Related Parties (Details) (Parenthetical)
57: R44 Notes Payable (Details Narrative) HTML 328K
58: R45 Schedule of Income Before Income Taxes (Details) HTML 30K
59: R46 Schedule of Component of Income Tax Expenses HTML 38K
(Benefit) (Details)
60: R47 Schedule of Effective Income Tax Rate HTML 41K
Reconciliation (Details)
61: R48 Schedule of Deferred Tax Assets (Details) HTML 36K
62: R49 Income Taxes (Details Narrative) HTML 35K
63: R50 Schedule of Warrant Activity (Details) HTML 56K
64: R51 Schedule of Outstanding and Exercisable (Details) HTML 50K
65: R52 Schedule of Stock Options Assumption Used HTML 37K
(Details)
66: R53 Summary of Stock Option Activity (Details) HTML 54K
67: R54 Stockholders? Deficiency (Details Narrative) HTML 281K
68: R55 Commitments and Contingencies (Details Narrative) HTML 69K
69: R56 Related Party Transactions (Details Narrative) HTML 32K
70: R57 Subsequent Events (Details Narrative) HTML 84K
73: XML IDEA XML File -- Filing Summary XML 129K
71: XML XBRL Instance -- form10-k_htm XML 2.14M
72: EXCEL IDEA Workbook of Financial Reports XLSX 103K
10: EX-101.CAL XBRL Calculations -- clcs-20211231_cal XML 182K
11: EX-101.DEF XBRL Definitions -- clcs-20211231_def XML 689K
12: EX-101.LAB XBRL Labels -- clcs-20211231_lab XML 1.37M
13: EX-101.PRE XBRL Presentations -- clcs-20211231_pre XML 966K
9: EX-101.SCH XBRL Schema -- clcs-20211231 XSD 210K
74: JSON XBRL Instance as JSON Data -- MetaLinks 397± 546K
75: ZIP XBRL Zipped Folder -- 0001493152-22-010133-xbrl Zip 738K
EXHIBIT 10.39(b)
AMENDMENT No. 2
TO SPONSORED RESEARCH AGREEMENT
This Amendment No. 2 to the Sponsored Research Agreement (“Amendment”) is made and entered into as of October 18, 2021 by and between Cell Source Limited (“Cell Source”) and The University of Texas M.D. Anderson Cancer Center (“MD Anderson”), a member institution of The University of Texas System (“System”).
RECITALS
| A. | Cell Source and MD Anderson entered into a Sponsored Research Agreement dated November 28, 2018 (the “Agreement”), which was amended on December 2nd, 2020. |
| B. | Cell Source and MD Anderson wish to amend the terms of the Agreement as set forth below. |
NOW, THEREFORE, it is hereby agreed as follows:
| 1. | The term of the agreement will be extended by one year, commencing on November 28th, 2021 through November 27th, 2022. | |
| 2. | Exhibit A of the Agreement shall include, as replacement and update to Exhibit A, the Exhibit attached hereto which describes the Work Plan for the Year starting 28th of November 2021 and ending 27th of November 2022. |
| 1. | Exhibit B of the Agreement shall include, as replacement and update to Exhibit B, the Exhibit attached hereto which describes the budget for the Year starting 28th of November 2021 and ending 27th of November 2022. As per the amended budget, the quarterly payments for the coming year will be $324,000 per quarter. |
| 2. | Except as expressly provided in this Amendment, all other terms, conditions and provisions of the Agreement shall continue in full force and effect as provided therein. |
IN WITNESS WHEREOF, Cell Source and MD Anderson have entered into this Amendment effective as of the date first set forth above.
| CELL SOURCE | THE UNIVERSITY OF TEXAS | |||
| M.D. ANDERSON CANCER CENTER | ||||
| By | /s/ Itamar Shimrat | By | /s/ Amy M. Moritz | |
| Itamar Shimrat | Name | Amy M. Moritz | ||
| Chief Executive Officer | Title | Assistant Director ORA | ||
| Date: | October 25, 2021 | Date: | 10/25/2021 | |
| Read & Understood: | ||||
| /s/Yair Reisner | ||||
| Principal Investigator | ||||
C:
Amended Exhibit A
Work plan for Cell Source: 28 November 2021 – 27 November 2022*
1. Studies with human cells :
A. Human VETO-project: Optimize transfection of our anti-viral veto cells with GMP grade CD19 vector from Orgenesis or from other companies.
1. Test the efficacy of anti-CD19 VETO-CAR T cells in vitro against CD19 tumor cells.
2. Test the efficacy of anti-CD19 VETO-CAR T cells in NSG mice bearing CD19 positive leukemic cells.
3. Compare the efficacy of VETO-CAR to regular CAR T cells in NSG mice.
4. Test the veto activity of VETO-CAR T cells compared to non-transduced VETO cells.
5. Characterize the genetic signature of our anti-viral Tcm by SCRNAseq.
6. Compare the efficacy of Tcm VETO-CAR to Effector memory VETO-CAR T cells in NSG mice.
B. Investigate the potential use of Veto cells directed against PR1 antigen expressed on AML tumor cells (in collaboration with Jeff Moldrem Lab).
1. Attempt to generate veto cells from donors vaccinated against PR1.
2. Test anti-PR1 veto cells for their activity against AML blasts in vitro and in-vivo.
C. Routine testing of immune reconstitution and immune tolerance induction in patients undergoing transplantation in our clinical trial.
2. Mouse studies:
A. Investigate the potential role of Tcm plus BM in the treatment of MS.
B. Generating Tcm against the WT1 Tumor antigen following immunization of mouse donors with WT1 peptides.
1. Optimize conditions for immunization
2. Optimize killing of WT1 tumors in-vitro and in-vivo.
C. Continue to investigate potential evasion of Tcm from NK mediated killing
* The proposed plan might be changed according to progress, and therefore, while some aims will be intensively investigated, others might not be performed.
C:
Amended Exhibit B
Budget
| Personnel | Base Salary | Cal Mths. | Effort | Salary | Fringe | Total | Grand Total | |||||||||||||||||||||
| PI | $ | 346,337.00 | 12.00 | 23 | % | $ | 79,657.51 | $ | 22,304.10 | $ | 101,961.61 | $ | 101,961.61 | |||||||||||||||
| Scientific Mgr | $ | 133,128.00 | 12.00 | 100 | % | $ | 133,128.00 | $ | 37,275.84 | $ | 170,403.84 | $ | 170,403.84 | |||||||||||||||
| Research Scientist | $ | 72,275.00 | 12.00 | 100 | % | $ | 72,275.00 | $ | 20,237.00 | $ | 92,512.00 | $ | 92,512.00 | |||||||||||||||
| Research Scientist | $ | 64,631.00 | 12.00 | 50 | % | $ | 32,315.50 | $ | 9,048.34 | $ | 41,363.84 | $ | 41,363.84 | |||||||||||||||
| Lab Technician | $ | 35,123.00 | 12.00 | 50 | % | $ | 17,561.50 | $ | 4,917.22 | $ | 22,478.72 | $ | 22,478.72 | |||||||||||||||
| Graduate Student | $ | 32,000.00 | 12.00 | 100 | % | $ | 31,539.50 | $ | 8,831.06 | $ | 40,370.56 | $ | 40,370.56 | |||||||||||||||
| Salary Total | $ | 469,090.57 | $ | 469,090.57 | ||||||||||||||||||||||||
Equipment or software Computer Consultant Costs | ||||||||||||||||||||||||||||
| Total | $ | 469,090.57 | $ | 469,090.57 | ||||
| Supplies | ||||||||
| Reagents, antibodies, pippettes, misc lab supplies | $ | 235,909.43 | $ | 235,909.43 | ||||
| Animal cost & Maintenance | $ | 80,000.00 | $ | 80,000.00 | ||||
| Travel (Domestic) | $ | 5,000.00 | $ | 5,000.00 | ||||
| Travel (International) | $ | 10,000.00 | $ | 10,000.00 | ||||
| Total | $ | 330,909.43 | $ | 330,909.43 | ||||
| Other Direct Costs | ||||||||
| Total | $ | - | $ | - | ||||
| Direct Costs | $ | 800,000.00 | $ | 800,000.00 | ||||
| Indirect Cost 62% | $ | 496,000.00 | $ | 496,000.00 | ||||
| Total Costs | $ | 1,296,000.00 | $ | 1,296,000.00 |
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 4/15/22 | |||
| For Period end: | 12/31/21 | NT 10-K | ||
| 10/25/21 | ||||
| 10/18/21 | ||||
| 11/28/18 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/08/23 Cell Source, Inc. 10-K 12/31/22 77:11M M2 Compliance LLC/FA |